Reoperation for the implantation of Corheart 6 biventricular assist devices due to severe right ventricular failure and aortic regurgitation following left ventricular assist device implantation.
{"title":"Reoperation for the implantation of Corheart 6 biventricular assist devices due to severe right ventricular failure and aortic regurgitation following left ventricular assist device implantation.","authors":"Yafeng Liu, Li Yin, Yiming Liu, Liqiong Xiao, Hongwei Shi, Xiaochun Song, Zhibing Qiu, Xin Chen","doi":"10.1177/03913988251351122","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We present the case of a 68-year-old patient who underwent secondary thoracotomy, implantation of a continuous-flow ventricular assist device (VAD) in a biventricular configuration, and aortic valve replacement (AVR) 2 years after receiving a continuous-flow left ventricular assist device (LVAD) and coronary artery bypass grafting (CABG), due to right ventricular failure, moderate aortic insufficiency, and damage to the original LVAD device cable.</p><p><strong>Case report: </strong>The patient initially received a Corheart 6 LVAD, CABG, and tricuspid annuloplasty due to end-stage heart failure resulting from ischemic cardiomyopathy and severe tricuspid regurgitation. Following the surgery, the patient was discharged with favorable outcomes. However, 2 years later, the patient was readmitted with severe right heart failure. Given the current shortage of heart donors, the decision was made to implant a Corheart 6 biventricular VAD (BiVAD) as destination therapy.</p><p><strong>Conclusion: </strong>Severe right ventricular failure is a well-recognized complication following continuous-flow LVAD implantation. In this case, it was successfully managed with BiVADs as destination therapy for this high-risk patient.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988251351122"},"PeriodicalIF":1.4000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Artificial Organs","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/03913988251351122","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: We present the case of a 68-year-old patient who underwent secondary thoracotomy, implantation of a continuous-flow ventricular assist device (VAD) in a biventricular configuration, and aortic valve replacement (AVR) 2 years after receiving a continuous-flow left ventricular assist device (LVAD) and coronary artery bypass grafting (CABG), due to right ventricular failure, moderate aortic insufficiency, and damage to the original LVAD device cable.
Case report: The patient initially received a Corheart 6 LVAD, CABG, and tricuspid annuloplasty due to end-stage heart failure resulting from ischemic cardiomyopathy and severe tricuspid regurgitation. Following the surgery, the patient was discharged with favorable outcomes. However, 2 years later, the patient was readmitted with severe right heart failure. Given the current shortage of heart donors, the decision was made to implant a Corheart 6 biventricular VAD (BiVAD) as destination therapy.
Conclusion: Severe right ventricular failure is a well-recognized complication following continuous-flow LVAD implantation. In this case, it was successfully managed with BiVADs as destination therapy for this high-risk patient.
期刊介绍:
The International Journal of Artificial Organs (IJAO) publishes peer-reviewed research and clinical, experimental and theoretical, contributions to the field of artificial, bioartificial and tissue-engineered organs. The mission of the IJAO is to foster the development and optimization of artificial, bioartificial and tissue-engineered organs, for implantation or use in procedures, to treat functional deficits of all human tissues and organs.